103 related articles for article (PubMed ID: 26524917)
1. [Variability of Reverse Transcriptase Gene and S Gene in Lamivudine-treated Chronic Hepatitis B Patients].
Qian F; Qin J; Li Dongli ; Wang Weihong ; Dai L
Bing Du Xue Bao; 2015 Jul; 31(4):433-9. PubMed ID: 26524917
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
4. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China.
Li XG; Liu BM; Xu J; Liu XE; Ding H; Li T
J Med Virol; 2012 Feb; 84(2):207-16. PubMed ID: 22170539
[TBL] [Abstract][Full Text] [Related]
5. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
[TBL] [Abstract][Full Text] [Related]
7. [Mutation analysis of the HBV reverse transcriptase in nucleos(t)ide-treated patients with chronic HBV infection].
Jiao XJ; Peng X; Jiao XM; Wang JS; Sun XW; Zhao PL; Wang SY; Liu JQ; Li T; Yang JX
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Dec; 26(6):453-5. PubMed ID: 23627028
[TBL] [Abstract][Full Text] [Related]
8. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
9. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
10. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
Fernández-Galindo DA; Sánchez-Ávila F; Bobadilla-Morales L; Gómez-Quiróz P; Bueno-Topete M; Armendáriz-Borunda J; Sánchez-Orozco LV
J Med Virol; 2015 Jun; 87(6):985-92. PubMed ID: 25732900
[TBL] [Abstract][Full Text] [Related]
11. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
12. Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.
Lei J; Wang Y; Wang LL; Zhang SJ; Chen W; Bai ZG; Xu LY
Virol J; 2013 Oct; 10():313. PubMed ID: 24160943
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
14. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
Su M; Xiang K; Li Y; Li Y; Deng J; Xu X; Yan L; Zhuang H; Li T
Infect Genet Evol; 2016 Jun; 40():275-281. PubMed ID: 27006281
[TBL] [Abstract][Full Text] [Related]
15. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
16. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.
Lee SY; Choi MS; Lee D; Lee JH; Koh KC; Paik SW; Yoo BC
J Korean Med Sci; 2005 Jun; 20(3):433-7. PubMed ID: 15953865
[TBL] [Abstract][Full Text] [Related]
17. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
18. Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B.
Ding H; Liu B; Zhao C; Yang J; Yan C; Yan L; Zhuang H; Li T
Antiviral Res; 2014 Feb; 102():29-34. PubMed ID: 24316031
[TBL] [Abstract][Full Text] [Related]
19. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Svicher V; Gori C; Trignetti M; Visca M; Micheli V; Bernassola M; Salpini R; Gubertini G; Longo R; Niero F; Ceccherini-Silberstein F; De Sanctis GM; Spanò A; Cappiello G; Perno CF
J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
[TBL] [Abstract][Full Text] [Related]
20. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
